Stay updated with the latest breaking news, headlines, and in-depth stories from The Capital Today.

Get In Touch

Stocks to buy: SBI Life, Varun Beverages, Ipca Labs

Summary

Brokerage firm Motilal Oswal Financial Services has shared top research ideas. The top stocks that are on the brokerage's radar are SBI Life Insurance, Varun Beverages, Ipca Labs.

Stocks to buy: SBI Life, Varun Beverages, Ipca Labs
Stocks to buy: SBI Life, Varun Beverages, Ipca Labs

Stocks To Buy Today: Brokerage firm Motilal Oswal Financial Services has recommended three stocks to buy. In a report published today (March 18), Motilal Oswal said that it is bullish on three stocks and recommended a BUY rating. The three stocks are SBI Life Insurance, Varun Beverages and Ipca Labs.

Let's take a look at the investment rationale along with their target price below:

SBI Life Insurance Share Price Target

On SBI Life Insurance, Motilal Oswal has reiterated a BUY rating with a target price of Rs 2400.

SBI Life Insurance (SBILIFE) has been a consistent compounder with FY20-25 APE CAGR at 15% vs. 6% for the industry (15% YoY in YTDFY26 vs 13% for the industry), supported by an extensive SBI branch network and one of the largest agent bases in the private life insurance industry. We expect the growth trajectory to remain stable at ~15% for FY26-28 as well.

Varun Beverages Share Price Target

On nVarun Beverages, Motilal Oswal has reiterated a BUY rating with a target price of Rs 550.

CY25 was a subdued year for Varun Beverages Limited (VBL), as unusually heavy rainfall led to weak beverage consumption, resulting in modest volume growth of 8% in the consolidated business and 2% in India, with realizations remaining largely flat. However, the long-term growth story remains intact, supported by structural drivers such as retail expansion, improved electrification, portfolio diversification, expansion into adjacent consumer products, and stronger cold-chain infrastructure.

Ipca Labs Share Price Target

On Ipca Labs, Motilal Oswal has reiterated a BUY rating with a target price of Rs 1820.

We expect IPCA to deliver a 13% revenue CAGR over FY26-28, led by robust performance in DF and a healthy pick-up in exports. We expect a CAGR of 17%/16% in EBITDA/PAT over FY26-28, led by better operating leverage. It values IPCA at 28x 12-month forward earnings.

More from Markets